AOP-Wiki

API

All Key Events

Showing 201 to 225 of 1907 Key Events

ID	Title	Event Component Count	Biological Organization	Created At	Last Updated	AOPs

421	Increased, glomerular rupture and renal hemorrhaging Short Name	2	Organ	Nov 29, 2016	Sep 16, 2017	53: ER agonism leading to reduced survival due to renal failure
422	Increased, nephropathy Short Name Increased, nephropathy	1	Individual	Nov 29, 2016	Dec 3, 2016	53: ER agonism leading to reduced survival due to renal failure
423	Increased, Clonal Expansion / Cell Proliferation to Form Pre-Neoplastic Altered Hepatic Foci Short Name	0		Nov 29, 2016	Nov 29, 2016	None
424	Inhibition, Na+/I- symporter (NIS) Short Name Inhibition, Na+/I- symporter (NIS)	1	Molecular	Nov 29, 2016	Apr 4, 2019	5 AOPs 65: XX Inhibition of Sodium Iodide Symporter and Subsequent Adverse Neurodevelopmental Outcomes in Mammals 54: Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment 134: Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals 176: Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis 110: Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse)
425	Decrease of Thyroidal iodide Short Name Thyroidal Iodide, Decreased	1	Cellular	Nov 29, 2016	Apr 4, 2019	4 AOPs 54: Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment 134: Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals 176: Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis 188: Iodotyrosine deiodinase (IYD) inhibition leading to altered amphibian metamorphosis
427	Down Regulation, K-Cl co-transporter 2 (KCC2) Short Name	0	Cellular	Nov 29, 2016	Nov 29, 2016	None
428	Delay, Developmental GABA shift Short Name Delay, Developmental GABA shift	0	Cellular	Nov 29, 2016	Nov 29, 2016	None
429	Cellular Proliferation and Clonal Expansion of Mutant Cells (Pre-neoplastic Foci), Alteration of cellular growth homeostasis Short Name	0		Nov 29, 2016	Nov 29, 2016	None
442	Decreased, Population trajectory Short Name Decreased, Population trajectory	1	Population	Nov 29, 2016	Apr 18, 2017	3 AOPs 435: Deposition of ionising energy leads to population decline via pollen abnormal 496: Androgen receptor agonism leading to reproduction dysfunction （in zebrafish） 549: Aromatase inhibition leads to reproductive toxicity (including growth and developmental toxicity) in adult female zebrafish
444	Increased, Atrioventricular block and bradycardia Short Name	2	Organ	Nov 29, 2016	Sep 16, 2017	94: Sodium channel inhibition leading to congenital malformations
445	Respiratory distress/arrest Short Name Respiratory distress/arrest	1	Organ	Nov 29, 2016	Dec 20, 2019	2 AOPs 16: Acetylcholinesterase inhibition leading to acute mortality 94: Sodium channel inhibition leading to congenital malformations
446	Reduction, fetal/adult testosterone Short Name Reduction of testosterone	1	Tissue	Nov 29, 2016	May 17, 2023	476: Adverse Outcome Pathways diagram related to PBDEs associated male reproductive toxicity
447	Reduction, Cholesterol transport in mitochondria Short Name	1	Cellular	Nov 29, 2016	Sep 16, 2017	2 AOPs 51: PPARα activation leading to impaired fertility in adult male rodents 18: PPARα activation in utero leading to impaired fertility in males
450	Decrease, Very low-density lipoprotein export capacity Short Name Decrease, VLDL export capacity	1	Cellular	Nov 29, 2016	Feb 12, 2026	57: AhR activation leading to hepatic steatosis
451	Inhibition, Mitochondrial fatty acid beta-oxidation Short Name	1	Molecular	Nov 29, 2016	Sep 16, 2017	3 AOPs 57: AhR activation leading to hepatic steatosis 58: NR1I3 (CAR) suppression leading to hepatic steatosis 61: NFE2L2/FXR activation leading to hepatic steatosis
454	Increased, Triglyceride formation Short Name Increased, Triglyceride formation	2	Cellular	Nov 29, 2016	Sep 16, 2017	2 AOPs 58: NR1I3 (CAR) suppression leading to hepatic steatosis 60: NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis
456	Suppression, Constitutive androstane receptor, NR1l3 Short Name	1	Molecular	Nov 29, 2016	Sep 16, 2017	58: NR1I3 (CAR) suppression leading to hepatic steatosis
457	Activation, SREBF1 Short Name Activation, SREBF1	2	Molecular	Nov 29, 2016	Sep 16, 2017	2 AOPs 58: NR1I3 (CAR) suppression leading to hepatic steatosis 62: AKT2 activation leading to hepatic steatosis
458	Increased, De Novo FA synthesis Short Name Increased, De Novo FA synthesis	1	Cellular	Nov 29, 2016	Sep 16, 2017	2 AOPs 58: NR1I3 (CAR) suppression leading to hepatic steatosis 61: NFE2L2/FXR activation leading to hepatic steatosis
459	Increase, Liver steatosis Short Name Increase, Liver steatosis	1	Organ	Nov 29, 2016	Feb 11, 2026	21 AOPs 58: NR1I3 (CAR) suppression leading to hepatic steatosis 60: NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis 61: NFE2L2/FXR activation leading to hepatic steatosis 62: AKT2 activation leading to hepatic steatosis 36: Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis 213: Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) 285: Inhibition of N-linked glycosylation leads to liver injury 318: Glucocorticoid Receptor activation leading to hepatic steatosis 517: Pregnane X Receptor (PXR) activation leads to liver steatosis 518: Liver X Receptor (LXR) activation leads to liver steatosis 529: Xenobiotic binding to peroxisome proliferator-activated receptors (PPARs) causes dysregulation of lipid metabolism leading to liver steatosis 232: NFE2/Nrf2 repression to steatosis 57: AhR activation leading to hepatic steatosis 494: AhR activation leading to liver fibrosis 591: DBDPE-induced DNA damage increase in liver leading to Non-alcoholic fatty liver disease via liver steatosis and inhibition of regeneration 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
460	Increased, Fatty acid uptake Short Name Increased, Fatty acid uptake	0	Cellular	Nov 29, 2016	Dec 3, 2016	None
461	Suppression, HNF4alpha Short Name Suppression, HNF4alpha	1	Molecular	Nov 29, 2016	Sep 16, 2017	59: HNF4alpha suppression leading to hepatic steatosis
462	Up Regulation, SCD-1 Short Name Up Regulation, SCD-1	1	Molecular	Nov 29, 2016	Sep 16, 2017	4 AOPs 58: NR1I3 (CAR) suppression leading to hepatic steatosis 60: NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis 57: AhR activation leading to hepatic steatosis 401: G protein-coupled estrogen receptor 1 (GPER) signal pathway in the lipid metabolism disrupting effects
463	Up Regulation, FAS Short Name Up Regulation, FAS	1	Molecular	Nov 29, 2016	Sep 16, 2017	58: NR1I3 (CAR) suppression leading to hepatic steatosis
465	Increased, Fatty acid influx Short Name Increased, FA Influx	1	Cellular	Nov 29, 2016	Feb 24, 2026	6 AOPs 57: AhR activation leading to hepatic steatosis 60: NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis 58: NR1I3 (CAR) suppression leading to hepatic steatosis 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress